Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
// Wenxin Zheng 1, 3, * , Kinga B. Skowron 2, 3, * , Jukes P. Namm 2, 3, 4, * , Byron Burnette 1, 3 , Christian Fernandez 1, 3 , Ainhoa Arina 1, 3 , Hua Liang 1, 3 , Michael T. Spiotto 1, 3 , Mitchell C. Posner 2 , Yang-Xin Fu 3, 5 , Ralph R. Weichselbaum 1, 3 1 Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA 2 Department of Surgery, University of Chicago, Chicago, IL, USA 3 The Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL, USA 4 Department of Surgery, Loma Linda University Health, Loma Linda, CA, USA 5 Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA * These authors contributed equally to this work Correspondence to: Ralph R. Weichselbaum, email: rrw@radonc.uchicago.edu Yang-Xin Fu, email: yang-xin.fu@utsouthwestern.edu Keywords: checkpoint blockade, T cell infiltration, radiation therapy, vaccination, tumor model Received: April 14, 2016 Accepted: May 20, 2016 Published: June 07, 2016 ABSTRACT The majority of cancer patients respond poorly to either vaccine or checkpoint blockade, and even to the combination of both. They are often resistant to high doses of radiation therapy as well. We examined prognostic markers of immune cell infiltration in pancreatic cancer. Patients with low CD8 + T cell infiltration and high PD-L1 expression (CD8 + T lo PD-L1 hi ) experienced poor outcomes. We developed a mouse tumor fragment model with a trackable model antigen (SIYRYYGL or SIY) to mimic CD8 + T lo PD-L1 hi cancers. Tumors arising from fragments contained few T cells, even after vaccination. Fragment tumors responded poorly to PD-L1 blockade, SIY vaccination or radiation individually. By contrast, local ionizing radiation coupled with vaccination increased CD8 + T cell infiltration that was associated with upregulation of CXCL10 and CCL5 chemokines in the tumor, but demonstrated modest inhibition of tumor growth. The addition of an anti-PD-L1 antibody enhanced the effector function of tumor-infiltrating T cells, leading to significantly improved tumor regression and increased survival compared to vaccination and radiation. These results indicate that sequential combination of radiation, vaccination and checkpoint blockade converts non-T cell-inflamed cancers to T cell-inflamed cancers, and mediates regression of established pancreatic tumors with an initial CD8 + T lo PD-L1 hi phenotype. This study has opened a new strategy for shifting “cold” to hot tumors that will respond to immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Self-citationThe Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 2×
“IR regulates several processes of the immune response, including production of inflammatory cytokines/chemokines, antigen exposure and presentation, T cell priming, as well as regulation of immune-suppressive cells and factors [9, 10].”
BackgroundReits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Self-citationEpigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · cited 1×
“Noteworthy, it was recently reported that epigenetic modulation of CXCL9 and CXCL10 promoted tumor T cell infiltration and enhanced efficacy of PD-L1 blockade [36].”
BackgroundChemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · cited 1×
“In addition to the lack of response to checkpoint inhibitors, non-T cell-inflamed melanomas are also characterized by the downregulation of chemokines and other immune markers [5].”
BackgroundLugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 1×
“IR has been reported to induce immunological cell death that releases antigen and other signals to stimulate the immune system [30], and may serve as an in situ vaccine to elicit T cell immunity [31].”
BackgroundCombination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 2×
“It is also notable that the definition of PD-L1 positivity and the presence of TILs was variable and limited by experimental techniques [22, 23].”
MethodLe, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553
Self-citationMarciscano, A. E., Ghasemzadeh, A., Nirschl, T. R., Theodros, D., Kochel, C. M., Francica, B. J., Muroyama, Y., Anders, R. A., Sharabi, A. B., Velarde, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3427 · Cited by 335
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Metadata
- Authors
- Zheng, W., Skowron, K. B., Namm, J. P., Burnette, B., Fernandez, C., Arina, A., Liang, H., Spiotto, M. T., Posner, M. C., Fu, Y.-X., & Weichselbaum, R. R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-06-07
- Volume
- 7
- Issue
- 28
- Pages
- 43039-43051
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2416541866
- Cited by
- 69
- References
- 11
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. https://app.cochat.ai/papers/10.18632/oncotarget.9915
- The paper
- Zheng, W., Skowron, K. B., Namm, J. P., Burnette, B., Fernandez, C., Arina, A., Liang, H., Spiotto, M. T., Posner, M. C., Fu, Y.-X., & Weichselbaum, R. R. (2016). Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. https://doi.org/10.18632/oncotarget.9915
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.